James Wade, senior analyst at Datamonitor Healthcare, talks about the pharmaceuticals industry which faces a "big patent cliff" at the moment, and discusses the outlook for next year.» Read More
On the heels of Eli Lilly's new anti-depressant drug for dogs (your dog is depressed? TAKE HIM FOR A WALK), a viewer alerted me to a new drug from a small company called Vical, in conjunction with Merck and Sanofi-Aventis. They've come up with a vaccine to treat melanoma in dogs. SKIN CANCER IN DOGS?
A woman apologized Monday for outing former Eli Lilly chairman and top State Department official Randall Tobias as a client of her escort service but said it was necessary to prove her company was doing legal business.
The resignation of a top State Department official following ties to an alleged prostitution ring is just the latest of a number of sex scandals to rock Washington, D.C.'s elite in years past.
Eli Lilly announced Wednesday it has received approval from the FDA to market Reconcile, the first selective serotonin reuptake inhibitor (SSRI) class of antidepressants approved by the FDA for treatment of canine separation anxiety in conjunction with behavior modification training.
Several other major drug companies were apparently interested in buying MedImmune, including Merck, Eli Lilly and possibly Novartis, CNBC’s David Faber reported Tuesday.
MedImmune may be close to completing a sale of the company just days after the drugmaker said it hired Goldman Sachs to explore opportunities, sources told CNBC's David Faber on Wednesday. "They are looking to get this deal done over the weekend," Faber said. "Monday morning is what I'm hearing."
Investors celebrated Tax Day with a broad-based rally and the S&P 500 closed at its highest level in nearly seven years, boosted by Citigroup's strong earnings report and a surge in M&A activity. "Expectations for this quarter are quite low and so far everything has beat, which has given the market a boost," said Barry Hyman, market strategist at EKN Financial.
Hey everyone. Here are today's trivia questions. The Bonus Bucks sure come in handy, so here you go: The video is worth $2,000 Bonus Bucks: Eli Lilly beat the street this morning and boosted its full-year guidance. By how much did they beat the street? And the news question is worth $1,000 Bonus Bucks: Sallie Mae has agreed to sell the company to J.C. Flowers & Co . How much will they pay per share?
Drug maker Eli Lilly reported first-quarter earnings and sales ahead of market expectations Monday and also boosted guidance for the year, thanks to strong sales of drugs for schizophrenia and depression.
John Lechleiter President and Chief Operating Officer of Eli Lilly, told CNBC’s “Squawk Box” that sales of Zyprexa, a drug used to treat schizophrenia, are strong. “We continue to be very bullish about Zyprexa,” Lechleiter said Monday. “We saw 6% sales growth in the U.S. this quarter. We had 14% sales growth internationally.”
Cramer can't help but be sad on a Friday -- that means no more Lightning Rounds until Monday. Home Gamers can make due with his calls on JetBlue, Citigroup, Eli Lilly, Crocs and more...Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Health care and insurance are two of the fastest-growing segments of the booming pet market. And big drug makers such as Pfizer, Novartis and Eli Lilly have taken note.
U.S. biotechnology company MedImmune has hired Goldman Sachs to explore a sale of the company, which has a market capitalization of $8.8 billion, people familiar with the situation said on Thursday.
The Hoosiers have questions on Dendreon, Eli Lilly and more. Luckily, Cramer's in town to tell them whether to buy or sell.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
After the trauma of a 416-point drop in the market, Cramer likes to go fishing – bottom fishing, actually. He has 25 years of experience angling through the wrecks of portfolios that belonged to less experienced fisherman and women, and today he’s going to share his secrets with you.
Could room-temperature Byetta heat up sales? Amylin Pharmaceuticals and Eli Lilly announced that the FDA says their diabetes drug Byetta (pronounced buy-ate-uh) doesn't have to be kept in the fridge anymore. Byetta is the twice-a-day stick-pen injectable drug that helps people lower their blood sugar and lose weight
U.S. stocks may have more room to run, but analysts say it might be wise to buy on the dips as the market looks for the next big catalyst to move it forward.
Stocks staged a late-afternoon rally after the Federal Reserve signaled that the outlook for inflation has improved while the economy continues to grow at a moderate pace.
The pharmaceutical company said fourth-quarter net income fell 81%, weighed down by liability and restructuring charges. However, excluding these items, Lilly's profits outpaced analysts' expectations.
So, an overwhelming majority of Icos shareholders voted for the Lilly buyout offer. Lilly originally offered $32 per share, but under pressure from proxy advisory firms and big investors, the company raised its bid to $34 per share. And: the United Kingdom's government health care program announced today that it is not going to spring for Erbitux or Avastin from Genentech and Roche.